CytoMed Therapeutics Limited Board of Directors

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Dr. Tien Wee Luk M.D.

Dr. Tien Wee Luk M.D.

Chief Clinical Officer

Ms. Yoong Ying Tan

Ms. Yoong Ying Tan

Chief Corporate Officer

Dr. Jieming Zeng M.D., Ph.D.

Dr. Jieming Zeng M.D., Ph.D.

Chief Scientific & Medical Officer and Director

Ms. Yvonne Goh

Ms. Yvonne Goh

Chief Financial Officer

Mr. Chee Kong Choo

Mr. Chee Kong Choo

Executive Chairman

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.